Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Espinoza-Delgado

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The Oncologist|August 8, 2002
Cancer vaccinesIgor Espinoza-Delgado
Expert Review of Anticancer Therapy|October 16, 2004
Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapyIgor Espinoza-Delgado, Richard W Childs
Cancer Journal (Sudbury, Mass.)|January 6, 2006
Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerationsAnthony J Murgo, Igor Espinoza-Delgado
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanismsWojciech Wojciechowski, Huifen Li, Shannon Marshall, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathwaysHuifen Li, Wojciech Wojciechowski, Chiara Dell'Agnola, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2Carmen S Garcia, Rafael E Curiel, James M Mwatibo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2005
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survivalEdward Gorak, Nancy Geller, Ramaprasad Srinivasan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaSuresh S Ramalingam, Chandra P Belani, Christopher Ruel, et al.
The Lancet. Oncology|October 4, 2005
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinibBipin N Savani, Ramaprasad Srinivasan, Igor Espinoza-Delgado, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The Oncologist|August 8, 2002
Cancer vaccinesIgor Espinoza-Delgado
Expert Review of Anticancer Therapy|October 16, 2004
Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapyIgor Espinoza-Delgado, Richard W Childs
Cancer Journal (Sudbury, Mass.)|January 6, 2006
Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerationsAnthony J Murgo, Igor Espinoza-Delgado
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanismsWojciech Wojciechowski, Huifen Li, Shannon Marshall, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathwaysHuifen Li, Wojciech Wojciechowski, Chiara Dell'Agnola, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2Carmen S Garcia, Rafael E Curiel, James M Mwatibo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2005
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survivalEdward Gorak, Nancy Geller, Ramaprasad Srinivasan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaSuresh S Ramalingam, Chandra P Belani, Christopher Ruel, et al.
The Lancet. Oncology|October 4, 2005
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinibBipin N Savani, Ramaprasad Srinivasan, Igor Espinoza-Delgado, et al.
Pageof 4